Sarah C Hellewell1,2,3, Stefania Mondello4, Alison Conquest3, Gerry Shaw5, Irina Madorsky5, Jay V Deng5, Lorraine Little6, Firas Kobeissy7, Nicole Bye2, Rinaldo Bellomo3,8, David J Cooper3,6,9, Shirley Vallance6, Jasmine Board6, Maria C Morganti-Kossmann6,10,11. 1. Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, Canada. 2. Department of Surgery, Alfred Hospital, Melbourne, Australia. 3. Department of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia. 4. Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina University, Messina, Italy. 5. EnCor Biotechnology Inc., Gainesville, FL. 6. Australian New Zealand Intensive Care Research Centre, Melbourne, Australia. 7. Department of Psychiatry and Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL. 8. Department of Intensive Care Research, Austin Health, Melbourne, Australia. 9. Department of Intensive Care, Alfred Hospital, Melbourne, Australia. 10. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. 11. Department of Child Health, Barrow Neurological Institute, University of Arizona, Phoenix, AZ.
Abstract
OBJECTIVE: To determine profiles of serum ubiquitin carboxy-terminal hydrolase L1 and phosphorylated neurofilament heavy-chain, examine whether erythropoietin administration reduce their concentrations, and whether biomarkers discriminate between erythropoietin and placebo treatment groups. DESIGN: Single-center, prospective observational study. SETTING: A sub-study of the erythropoietin-traumatic brain injury clinical trial, conducted at the Alfred Hospital, Melbourne, Australia. PATIENTS: Forty-four patients with moderate-to-severe traumatic brain injury. INTERVENTIONS:Epoetin alfa 40,000 IU or 1 mL sodium chloride 0.9 as subcutaneous injection within 24 hours of traumatic brain injury. MEASUREMENTS AND MAIN RESULTS:Ubiquitin carboxy-terminal hydrolase L1, phosphorylated neurofilament heavy-chain, and erythropoietin concentrations were measured in serum by enzyme-linked immunosorbent assay from D0 (within 24 hr of injury, prior to erythropoietin/vehicle administration) to D5. Biomarker concentrations were compared between injury severities, diffuse versus focal traumatic brain injury and erythropoietin or placebo treatment groups. Ubiquitin carboxy-terminal hydrolase L1 peaked at 146.0 ng/mL on D0, significantly decreased to 84.30 ng/mL on D1, and declined thereafter. Phosphorylated neurofilament heavy-chain levels were lowest at D0 and peaked on D5 at 157.9 ng/mL. D0 ubiquitin carboxy-terminal hydrolase L1 concentrations were higher in diffuse traumatic brain injury. Peak phosphorylated neurofilament heavy-chain levels on D3 and D4 correlated with Glasgow Outcome Score-Extended, predicting poor outcome. Erythropoietin did not reduce concentrations of ubiquitin carboxy-terminal hydrolase L1 or phosphorylated neurofilament heavy-chain. CONCLUSIONS: Serum ubiquitin carboxy-terminal hydrolase L1 and phosphorylated neurofilament heavy-chain increase after traumatic brain injury reflecting early neuronal and progressive axonal injury. Consistent with lack of improved outcome in traumatic brain injury patients treated with erythropoietin, biomarker concentrations and profiles were not affected by erythropoietin. Pharmacokinetics of erythropoietin suggest that the dose given was possibly too low to exert neuroprotection.
RCT Entities:
OBJECTIVE: To determine profiles of serum ubiquitin carboxy-terminal hydrolase L1 and phosphorylated neurofilament heavy-chain, examine whether erythropoietin administration reduce their concentrations, and whether biomarkers discriminate between erythropoietin and placebo treatment groups. DESIGN: Single-center, prospective observational study. SETTING: A sub-study of the erythropoietin-traumatic brain injury clinical trial, conducted at the Alfred Hospital, Melbourne, Australia. PATIENTS: Forty-four patients with moderate-to-severe traumatic brain injury. INTERVENTIONS: Epoetin alfa 40,000 IU or 1 mL sodium chloride 0.9 as subcutaneous injection within 24 hours of traumatic brain injury. MEASUREMENTS AND MAIN RESULTS: Ubiquitin carboxy-terminal hydrolase L1, phosphorylated neurofilament heavy-chain, and erythropoietin concentrations were measured in serum by enzyme-linked immunosorbent assay from D0 (within 24 hr of injury, prior to erythropoietin/vehicle administration) to D5. Biomarker concentrations were compared between injury severities, diffuse versus focal traumatic brain injury and erythropoietin or placebo treatment groups. Ubiquitin carboxy-terminal hydrolase L1 peaked at 146.0 ng/mL on D0, significantly decreased to 84.30 ng/mL on D1, and declined thereafter. Phosphorylated neurofilament heavy-chain levels were lowest at D0 and peaked on D5 at 157.9 ng/mL. D0 ubiquitin carboxy-terminal hydrolase L1 concentrations were higher in diffuse traumatic brain injury. Peak phosphorylated neurofilament heavy-chain levels on D3 and D4 correlated with Glasgow Outcome Score-Extended, predicting poor outcome. Erythropoietin did not reduce concentrations of ubiquitin carboxy-terminal hydrolase L1 or phosphorylated neurofilament heavy-chain. CONCLUSIONS: Serum ubiquitin carboxy-terminal hydrolase L1 and phosphorylated neurofilament heavy-chain increase after traumatic brain injury reflecting early neuronal and progressive axonal injury. Consistent with lack of improved outcome in traumatic brain injurypatients treated with erythropoietin, biomarker concentrations and profiles were not affected by erythropoietin. Pharmacokinetics of erythropoietin suggest that the dose given was possibly too low to exert neuroprotection.
Authors: Frederick Korley; Qi Pauls; Sharon D Yeatts; Courtney Marie Cora Jones; Emily Corbett-Valade; Robert Silbergleit; Michael Frankel; William Barsan; Nathan D Cahill; Jeffrey J Bazarian; David W Wright Journal: J Neurotrauma Date: 2021-01-25 Impact factor: 4.869
Authors: Shenandoah Robinson; Jesse L Winer; Lindsay A S Chan; Akosua Y Oppong; Tracylyn R Yellowhair; Jessie R Maxwell; Nicholas Andrews; Yirong Yang; Laurel O Sillerud; William P Meehan; Rebekah Mannix; Jonathan L Brigman; Lauren L Jantzie Journal: Front Neurol Date: 2018-06-19 Impact factor: 4.003
Authors: Johannes Ehler; Axel Petzold; Matthias Wittstock; Stephan Kolbaske; Martin Gloger; Jörg Henschel; Amanda Heslegrave; Henrik Zetterberg; Michael P Lunn; Paulus S Rommer; Annette Grossmann; Tarek Sharshar; Georg Richter; Gabriele Nöldge-Schomburg; Martin Sauer Journal: PLoS One Date: 2019-01-24 Impact factor: 3.240
Authors: Adam Anad; Miriam K Barker; Jessica A Katanga; Konstantinos Arfanakis; Leslie R Bridges; Margaret M Esiri; Jeremy D Isaacs; Sonja Prpar Mihevc; Anthony C Pereira; Julie A Schneider; Atticus H Hainsworth Journal: J Neuropathol Exp Neurol Date: 2022-02-24 Impact factor: 3.685
Authors: Emily L Dennis; David Baron; Brenda Bartnik-Olson; Karen Caeyenberghs; Carrie Esopenko; Frank G Hillary; Kimbra Kenney; Inga K Koerte; Alexander P Lin; Andrew R Mayer; Stefania Mondello; Alexander Olsen; Paul M Thompson; David F Tate; Elisabeth A Wilde Journal: Hum Brain Mapp Date: 2020-06-01 Impact factor: 5.038